Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data
about
Pre-hospital versus in-hospital thrombolysis for ST-elevation myocardial infarctionPre-hospital versus in-hospital thrombolysis for acute myocardial infarctionManagement of acute coronary syndromes with fondaparinuxLow-molecular-weight heparins as adjunctive therapy to thrombolytics: extracting the best data.Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion: a Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial InfaSafety and effectiveness of enoxaparin following fibrinolytic therapy: Results of the Acute Myocardial Infarction (AMI)-QUEBEC registryUse of anticoagulants in ST-segment elevation myocardial infarction patients; a focus on low-molecular-weight heparin.Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction.Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis.A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: a WEST sub-study.A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation.ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis.Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI patients treated with tenecteplase.Corrections
P2860
Q22252960-432130FB-500E-46B7-B731-3DFF2B98EBDAQ24197751-84E4147E-0DD0-48FC-9056-B9AD86828AB7Q28219642-659FFA3D-7297-4076-9992-CEB1DA582C07Q31039802-666281E3-06CF-440A-8F11-FC9578DF8244Q33595928-C4660E59-27BE-4079-A453-75A0663F1017Q34196711-ADD6D697-2DFF-48CC-9CB2-457B0E096AB8Q37047875-3DC8FB1E-E5B8-4CBC-83CC-E91E94BD052EQ37167513-D6BA56E6-1007-4541-AC19-E2B9BA4F2AF3Q38545163-FE8FFD91-5858-4631-BECE-923B99121DD7Q39786426-B2AAB61F-C7D4-4799-B80D-2C36AFA8B821Q45959804-D1D4766C-EFCE-4669-B005-C3FB16A19F9AQ50665407-8116E0EB-0A6E-45D8-B605-ADFE801F413EQ53656617-58F90382-370B-411C-879E-763C148B76A3Q57484062-88D0AAA0-EB83-4247-8E6D-D244FFB87DDB
P2860
Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Efficacy and safety of unfract ...... s of ASSENT-3 and -3 PLUS data
@ast
Efficacy and safety of unfract ...... s of ASSENT-3 and -3 PLUS data
@en
type
label
Efficacy and safety of unfract ...... s of ASSENT-3 and -3 PLUS data
@ast
Efficacy and safety of unfract ...... s of ASSENT-3 and -3 PLUS data
@en
prefLabel
Efficacy and safety of unfract ...... s of ASSENT-3 and -3 PLUS data
@ast
Efficacy and safety of unfract ...... s of ASSENT-3 and -3 PLUS data
@en
P2093
P2860
P50
P356
P1476
Efficacy and safety of unfract ...... s of ASSENT-3 and -3 PLUS data
@en
P2093
ASSENT-3 and ASSENT-3 PLUS Investigators
Patrick Goldstein
Thierry Danays
Wei-Ching Chang
P2860
P304
P356
10.1503/CMAJ.051410
P407
P577
2006-05-01T00:00:00Z